Cultivation Capital Life Sciences

Rick Ryan has over 35 years of experience in business management and technology development within the life science industry, holding executive roles at both multinationals and early-stage ventures. He was VP of the Drug Discovery & Development business unit at Millipore until 2010 and previously served as President of LINCO Research and held Director-level positions at Monsanto. He currently serves as CEO of Apertus Pharmaceuticals, and holds a B.S. in Chemistry, a PhD in Biochemistry, and an executive MBA from Washington University in St. Louis.

Bobby Sandage is Managing Director at the Paula and Rodger Riney Foundation and Lightchain Capital, LLC, a General Partner in Cultivation Capital Life Sciences Fund II, and serves on the boards of Predicta Biosciences, Immunophotonics, and Endevica Bio. His earlier roles include President and CEO of Euclises and of Coronado Biosciences, VP of Embedded Therapeutics at Covidien Pharmaceuticals, and executive vice president of research and development and chief scientific officer at Indevus Pharmaceuticals, along with senior drug development positions at DuPont Merck Pharmaceutical Company and DuPont Critical Care. He is an adjunct professor of pharmaceutical sciences at the Southern Illinois University at Edwardsville School of Pharmacy, holds a Ph.D. in clinical pharmacy from Pur